EFFECT OF A DİETİTİAN-SUPERVİSED LOW-FODMAP DİET VERSUS STANDARD WRİTTEN ADVİCE ON GASTROİNTESTİNAL SYMPTOMS AND INFLAMMATORY BİOMARKERS İN IRRİTABLE BOWEL SYNDROME: A RANDOMİZED CONTROLLED TRİAL
Background:
Irritable Bowel Syndrome (IBS) is the most prevalent functional gastrointestinal (GI) pathology among GI disorders. Various dietary interventions, particularly the low-FODMAP diet, are employed to alleviate IBS symptoms.
Study Population & Design:
This study will include 78 adult patients, aged 18-65, diagnosed with IBS according to Rome IV criteria at the Biruni University Faculty of Medicine Hospital Gastroenterology Outpatient Clinic. Participants will be divided into two parallel groups:
Group 1 (n=39): Will receive dietary intervention solely through physician follow-up (provided with a standard hospital brochure listing prohibited foods).
Group 2 (n=39): Will receive structured, personalized dietary intervention through individualized nutritional counseling by a dietitian.
Duration: The low-FODMAP diet intervention for both groups will last for 8 weeks.
Outcome Measures:
At baseline (week 0) and at the conclusion of the study (week 8), the following assessments will be conducted:
Clinical Scores: IBS Symptom Severity Score (IBS-SSS) and the 15-item Gastrointestinal Symptom Rating Scale (GSRS).
Biomarkers: Hs-CRP and fecal calprotectin levels analyzed from blood and stool samples.
Objective:
The primary objective is to determine the impact of individualized nutritional counseling on GI symptoms and inflammatory biomarkers (hs-CRP, fecal calprotectin) during a low-FODMAP diet. Secondary objectives include evaluating the significance of the dietitian's role and observing how lifestyle factors (sleep and physical activity) influence symptom outcomes alongside nutritional therapy.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
The low-FODMAP diet, developed for the treatment of IBS, is defined as a dietary regimen that restricts fermentable oligosaccharides, disaccharides, monosaccharides, and polyols-which are short-chain carbohydrates with limited or poor absorption.
Study Timeline and Interventions:
First Week: A 31-item "Data Collection Form" covering socio-demographic characteristics, health information, and nutritional habits will be administered.
Daily Monitoring: Daily records of the "Bristol Stool Scale" (BSS) will be maintained throughout the study.
Study Duration: The low-FODMAP diet intervention will be implemented for a total duration of 8 weeks.
Face-to-Face Assessments (Conducted at Baseline and Conclusion):
At the beginning and end of the study, the following assessments will be conducted face-to-face with the participants:
- 24-hour Dietary Recall
- Anthropometric measurements
- Frequency of FODMAP-sourced food consumption over the past month
- 7-item "International Physical Activity Questionnaire - Short Form" (IPAQ-SF)
- 5-item "IBS Symptom Severity Score" (IBS-SSS)
- 15-item "Gastrointestinal Symptom Rating Scale" (GSRS)
- 8-item "Epworth Sleepiness Scale" (ESS)
Laboratory Analysis:
Hs-CRP and fecal calprotectin levels will be analyzed from blood and stool samples collected at baseline and at the conclusion of the study.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Istanbul
-
Istanbul, Istanbul, Турция (Туркие)
- Biruni University Faculty of Medicine Hospital
-
Istanbul, Istanbul, Турция (Туркие)
- Biruni University
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Описание
Inclusion Criteria:
- Adults aged 18-65 years.
- Diagnosed with IBS according to the Rome IV criteria.
Exclusion Criteria:
- Use of antibiotics, NSAIDs, oral contraceptives, or hormone therapy during the study.
- Pregnancy or breastfeeding.
- Diagnosis of celiac disease
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Dietitian group
A dietitian planned the low FODMAP diet for the first group (n=31) through individual dietary counselling.
|
This intervention consists of an 8-week low-FODMAP dietary regimen aimed at restricting the intake of short-chain carbohydrates, including fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. The intervention is administered through two distinct protocols to compare delivery methods: one group receives standard hospital care consisting of a brief physician follow-up accompanied by a standard educational brochure listing prohibited foods, while the other group receives structured, individualized nutritional counseling and personalized meal planning led by a professional dietitian. |
|
Активный компаратор: Doctor group
The second group (n=19) was given a brochure on the low FODMAP diet, as is routine in the hospital, listing foods prohibited by the gastroenterologist.
|
This intervention consists of an 8-week low-FODMAP dietary regimen aimed at restricting the intake of short-chain carbohydrates, including fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. The intervention is administered through two distinct protocols to compare delivery methods: one group receives standard hospital care consisting of a brief physician follow-up accompanied by a standard educational brochure listing prohibited foods, while the other group receives structured, individualized nutritional counseling and personalized meal planning led by a professional dietitian. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
IBS-SSS
Временное ограничение: From enrollment to the end of treatment at 8 weeks
|
Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS).
The IBS-SSS consists of 5 questions, each scored from 0 to 100, with a maximum possible total score of 500.
It determines the severity of abdominal pain, abdominal pain frequency, abdominal bloating severity, satisfaction with bowel habits, and the impact of the disease on quality of life.
Total scores are classified as follows: 75-174 points = mild IBS, 175-299 points = moderate IBS, and greater than or equal to 300 points = severe IBS.
Higher scores indicate more severe IBS symptoms.
|
From enrollment to the end of treatment at 8 weeks
|
|
GSRS
Временное ограничение: From enrollment to the end of treatment at 8 weeks
|
Gastrointestinal Symptom Rating Scale (GSRS).
The GSRS is a 15-item questionnaire that uses a 5-point Likert scale to assess the severity of gastrointestinal symptoms across 5 subscales: abdominal pain, reflux, diarrhoea, indigestion, and constipation.
Scores are aggregated to determine symptom severity, where higher scores represent a higher severity of gastrointestinal symptoms.
|
From enrollment to the end of treatment at 8 weeks
|
|
Fecal Calprotectin
Временное ограничение: From enrollment to the end of treatment at 8 weeks
|
Fecal calprotectin levels will be analyzed from stool samples collected from participants to evaluate gastrointestinal inflammation.
|
From enrollment to the end of treatment at 8 weeks
|
|
Hs-CRP
Временное ограничение: From enrollment to the end of treatment at 8 weeks
|
High-Sensitivity C-Reactive Protein (hs-CRP).
Hs-CRP levels will be analyzed from blood samples collected from individuals to monitor systemic biochemical findings of inflammation.
|
From enrollment to the end of treatment at 8 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Anthropometric measurement data
Временное ограничение: From enrollment to the end of treatment at 8 weeks
|
height in cm, body weight in kg, waist circumference in cm, hip circumference in cm, body composition and bioelectrical impedance analysis (BIA) measurements
|
From enrollment to the end of treatment at 8 weeks
|
|
IPAQ-SF
Временное ограничение: From enrollment to the end of treatment at 8 weeks
|
The IPAQ-SF is a seven-item measure that assesses individuals' physical activity levels over the past seven days.
The scale inquires about walking, moderate and vigorous physical activities, and time spent sitting, and physical activity level is calculated in MET-minutes per week
|
From enrollment to the end of treatment at 8 weeks
|
|
Epworth Sleepiness Scale (ESS)
Временное ограничение: From enrollment to the end of treatment at 8 weeks
|
The ESS is an eight-item self-report measure that assesses an individual's likelihood of falling asleep in various everyday situations
|
From enrollment to the end of treatment at 8 weeks
|
|
Data Collection Form
Временное ограничение: At the beginning of the study
|
At the beginning of the study, a 31-item Data Collection Form; covering the sociodemographic characteristics, health information and dietary habits of participating patients was administered.
|
At the beginning of the study
|
|
Daily Total FODMAP Intake
Временное ограничение: From enrollment to the end of treatment at 8 weeks
|
Food consumption records were taken for 3 days before and after the diet.
The data was entered into the Bebis program.
Food consumption records were calculated using the Nutrition Information System (BeBiS, version 9, Germany) for energy, macronutrients, micronutrients and FODMAP amounts (total FODMAP (g) = lactose (g) + oligosaccharides (g) + mannitol (g) + sorbitol (g)).
Free fructose, a monosaccharide, could not be included in this programme as it could not be calculated.
|
From enrollment to the end of treatment at 8 weeks
|
Соавторы и исследователи
Спонсор
Следователи
- Учебный стул: Sevde KAHRAMAN, Asst. Prof., Biruni University
- Директор по исследованиям: Zeynep Çavdar, Master's student and dietitan, Biruni University
- Главный следователь: Koray Koçhan, Specialist of Gastroenterology, Department of Gastroenterology, Biruni University Faculty of Medicine Hospital
- Главный следователь: Huri Demirci, PhD, Associate Professor, Biruni University
- Учебный стул: Fatma Çelik, PhD, Professor, Biruni University
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 2015-KAEK-80-23-49/SKLOWFODMAP
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .